We have all lost relatives, friends, patients by pulmonary embolism, let alone seen the devastating longterm effects of deep vein thrombosis.
The recent landmark trials – in USA( Womens’ Health Initiative), and Oulu Finland- showed that (like metformin therapy), non-human ie xenohormone therapy eg premarin and prempro reduce all major longterm degenerative diseases by between a third and half when given appropriately soon after menopause for up to 10 years – breast and colon cancer, diabetes, ischemic heart and brain disease, fractures, memory and visual loss, and breast-cancer- and all-cause -mortality.
Two major shortterm adverse effects of oral sexhormone therapy OHT – deep vein thrombosis and gallstones- were relatively rare. But worse, it is well proven that such OHT doubles the rate of measurable postmenopausal fat gain and usually associated muscle loss.
A new study in France (Canonico et al) of hormone replacement therapy HRT, in 80 000 postmenopausal women PMW over 10 years, shows that oral estrogen therapy OET and commonly used progestins, eg premarin/ prempro, doubles the risk of deep vein thrombosis compared to non-users. The overall risk of deep vein thrombosis was only about 0.07% per year or 7cases per 1000 women over 10 years. But there was no significant association with transdermal estrogen, progesterone, pregnanes, and nortestosterone.
As this column has regularly reviewed, this French study thus again confirms that it is negligent, immoral to expose women even shortterm to the risks of hugely marketed OHT- especially with non-human ie xenohormones- when appropriate balanced physiological non-oral human hormones via the skin/mucosa, although more costly, give only major benefit, adding years to health and life.